Physiological and QoL Benefits of Qi-Gong in Post-acute Sequelae of Covid-19 (QG-PASC)

March 12, 2025 updated by: POCHIWU

The Effects of Qi-gong on Physiology and Quality of Life in Patients with Post-acute Sequelae of Covid-19

The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC).

Study Objectives:

To assess whether Qi-Gong improves physiological function in individuals with PASC.

To evaluate whether Qi-Gong enhances quality of life in individuals with PASC.

Study Design:

If a comparison group is included, researchers will compare Qi-Gong with standard care to assess its effectiveness.

Participant Involvement:

Practice Qi-Gong three times per week for three months. Record physiological data monthly.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Taiwan
      • New Taipei City, Taiwan
        • Recruiting
        • Renhe nursing home
        • Contact:
      • Taipei, Taiwan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • PASC
  • above 20 y/o

Exclusion Criteria:

  • Those who cannot cooperate
  • Severe schizophrenia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Qi-Gong Group
Experimental Group :Qi-Gong(yijinjing)
Behavioral: QI-GONG and control
QIGONG
No Intervention: routine care Group
Control Group:routine care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pulmonary Function Test (Forced vital capacity)
Time Frame: From enrollment to the end of treatment at 12 weeks
FVC，over 80% is better
From enrollment to the end of treatment at 12 weeks
Pulmonary Function Test (FEV1)
Time Frame: From enrollment to the end of treatment at 12 weeks
FEV1，over 80% is better
From enrollment to the end of treatment at 12 weeks
Pulmonary Function Test (FVCFEV1)
Time Frame: From enrollment to the end of treatment at 12 weeks
FVCFEV1，over 80% is better
From enrollment to the end of treatment at 12 weeks
Heart rate variability
Time Frame: From enrollment to the end of treatment at 12 weeks
Low Frequency,40%-60%
From enrollment to the end of treatment at 12 weeks
Heart rate variability
Time Frame: From enrollment to the end of treatment at 12 weeks
High Frequency,40%-60%
From enrollment to the end of treatment at 12 weeks
Heart rate variability
Time Frame: From enrollment to the end of treatment at 12 weeks
LF/HF,0.6-2.5
From enrollment to the end of treatment at 12 weeks
Heart rate variability
Time Frame: From enrollment to the end of treatment at 12 weeks
Heart rate variability ,25ms-70ms
From enrollment to the end of treatment at 12 weeks
Quality of Life(The short version of the World Health Organization Quality of Life ，WHOQOL-BREF)
Time Frame: From enrollment to the end of treatment at 12 weeks
WHOQOL-BREF 4 domains,and each one score is 4 - 20. more score more better
From enrollment to the end of treatment at 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

POCHIWU

Investigators

  • Principal Investigator: Mei-Hua Wang, National Taipei University of Nursing and Health Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 2, 2024

Primary Completion (Estimated)

April 7, 2025

Study Completion (Estimated)

April 7, 2025

Study Registration Dates

First Submitted

February 15, 2025

First Submitted That Met QC Criteria

March 12, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 12, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CTH-113-3-5-030
  • NTUNHS (Registry Identifier: National Taipei University of Nursing and Health Sciences)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe